Search results for " stroma"

showing 10 items of 172 documents

IL-17A-associated IKK-α signaling induced TSLP production in epithelial cells of COPD patients.

2018

Thymic stromal lymphopoietin (TSLP) is a cytokine expressed in the epithelium, involved in the pathogenesis of chronic disease. IL-17A regulates airway inflammation, oxidative stress, and reduction of steroid sensitivity in chronic obstructive pulmonary disease (COPD). TSLP and IL-17A were measured in induced sputum supernatants (ISs) from healthy controls (HC), healthy smokers (HS), and COPD patients by enzyme-linked immunosorbent assay. Human bronchial epithelial cell line (16HBE) and normal bronchial epithelial cells were stimulated with rhIL-17A or ISs from COPD patients to evaluate TSLP protein and mRNA expression. The effects of the depletion of IL-17A in ISs, an anticholinergic drug,…

0301 basic medicineMalemedicine.medical_treatmentClinical Biochemistrylcsh:MedicineCell CountBiochemistryCholinergic AntagonistsPathogenesisHistonesPulmonary Disease Chronic Obstructivelcsh:QD415-436COPDKinaseInterleukin-17AcetylationI-kappa B KinaseRespiratory Function TestsCytokinemedicine.anatomical_structureMolecular MedicineCytokinesFemaleProtein BindingSignal TransductionThymic stromal lymphopoietinEnzyme-Linked Immunosorbent AssayRespiratory MucosaArticleCell Linelcsh:Biochemistry03 medical and health sciencesThymic Stromal LymphopoietinmedicineGene silencingCOPDHumansMolecular Biologybusiness.industrylcsh:RSputumEpithelial Cellsmedicine.diseaseEpitheliumrespiratory tract diseases030104 developmental biologyCell cultureCancer researchbusinessBiomarkersExperimentalmolecular medicine
researchProduct

Type and gene location of kit mutations predict progression-free survival to first-line imatinib in gastrointestinal stromal tumors: A look into the …

2021

In previous studies on localized GISTs, KIT exon 11 deletions and mutations involving codons 557/558 showed an adverse prognostic influence on recurrence-free survival. In the metastatic setting, there are limited data on how mutation type and codon location might contribute to progression-free survival (PFS) variability to first-line imatinib treatment. We analyzed the type and gene location of KIT and PDGFRA mutations for 206 patients from a GIST System database prospectively collected at an Italian reference center between January 2005 and September 2020. By describing the mutational landscape, we focused on clinicopathological characteristics according to the critical mutations and inve…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyStromal cellPDGFRAlcsh:RC254-28203 medical and health sciencesExon0302 clinical medicinePredictive biomarkersInternal medicineGene duplicationmedicineGastrointestinal stromal tumorsProgression-free survivalGeneneoplasmsGiSTbusiness.industryImatinibKITlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens030104 developmental biologyOncology030220 oncology & carcinogenesisImatinibbusinessMutationsmedicine.drugGIST
researchProduct

Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice

2017

Background: Regorafenib (REG) has now been approved as the standard third-line therapy in metastatic gastrointestinal stromal tumour (GIST) patients at the recommended dose and schedule of 160 mg once daily for the first 3 weeks of each 4-week cycle. However, it has a relevant toxicity profile that mainly occurs within the first cycles of therapy, and dose and schedule adjustments are often required to reduce the frequency or severity of adverse events and to avoid early treatment discontinuation. To date, large amounts of data on the use of REG in metastatic GIST patients in daily clinical practice are not available, and we lack information about how this treatment personalization really a…

0301 basic medicineOncologymedicine.medical_specialtyScheduleStromal cellSettore MED/06 - Oncologia Medicalcsh:RC254-282PersonalizationNO03 medical and health scienceschemistry.chemical_compound0302 clinical medicinetyrosine kinase inhibitorQuality of lifeInternal medicineRegorafenibtyrosine kinase inhibitorsmedicineOriginal Researchreferral centresGiSTbusiness.industryGIST; personalized treatment; quality of life; referral centres; regorafenib; tyrosine kinase inhibitors; OncologyGastrointestinal stromal tumourslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenspersonalized treatmentClinical PracticeGIST; personalized treatment; quality of life; referral centres; regorafenib; tyrosine kinase inhibitorsreferral centre030104 developmental biologychemistryquality of lifeOncology030220 oncology & carcinogenesisregorafenibbusinessGIST personalized treatment quality of life referral centres regorafenib tyrosine kinase inhibitorsGIST
researchProduct

Long-Term in vivo Evaluation of Orthotypical and Heterotypical Bioengineered Human Corneas.

2020

Purpose: Human cornea substitutes generated by tissue engineering currently require limbal stem cells for the generation of orthotypical epithelial cell cultures. We recently reported that bioengineered corneas can be fabricated in vitro from a heterotypical source obtained from Wharton’s jelly in the human umbilical cord (HWJSC). Methods: Here, we generated a partial thickness cornea model based on plastic compression nanostructured fibrin-agarose biomaterials with cornea epithelial cells on top, as an orthotypical model (HOC), or with HWJSC, as a heterotypical model (HHC), and determined their potential in vivo usefulness by implantation in an animal model. Results: No major side effects …

0301 basic medicinePathology02 engineering and technology:Chemicals and Drugs::Carbohydrates::Polysaccharides::Sepharose [Medical Subject Headings]Umbilical cord:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]heterotypical human corneaTissue engineering:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Lagomorpha::Rabbits [Medical Subject Headings]Cornea:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Optical Imaging::Tomography Optical::Tomography Optical Coherence [Medical Subject Headings]:Organisms::Eukaryota::Animals [Medical Subject Headings]:Technology and Food and Beverages::Technology Industry and Agriculture::Manufactured Materials::Biomedical and Dental Materials::Biocompatible Materials [Medical Subject Headings]Slit lamp021001 nanoscience & nanotechnologymedicine.anatomical_structure:Anatomy::Sense Organs::Eye::Anterior Eye Segment::Cornea [Medical Subject Headings]tissue engineeringStem cell0210 nano-technologyBiotechnology:Chemicals and Drugs::Amino Acids Peptides and Proteins::Proteins::Blood Proteins::Fibrin [Medical Subject Headings]medicine.medical_specialtyHistologyStromal celllcsh:BiotechnologyBiomedical EngineeringCélulas madre mesenquimatosasBioengineering:Anatomy::Embryonic Structures::Fetus::Umbilical Cord [Medical Subject Headings]:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Models Animal [Medical Subject Headings]03 medical and health sciencesIn vivolcsh:TP248.13-248.65medicine:Anatomy::Cells::Connective Tissue Cells::Stromal Cells::Mesenchymal Stromal Cells [Medical Subject Headings]:Technology and Food and Beverages::Technology Industry and Agriculture::Engineering::Bioengineering::Cell Engineering::Tissue Engineering [Medical Subject Headings]Wharton’s jelly stem cellsbioengineered corneabusiness.industryTissue engineringeye diseasesEpitheliumCórnea:Anatomy::Cells::Epithelial Cells [Medical Subject Headings]:Anatomy::Tissues::Connective Tissue::Wharton Jelly [Medical Subject Headings]030104 developmental biologyIngeniería de tejidossense organsbusinessartificial cornea
researchProduct

Neuroblastoma patient-derived orthotopic xenografts reflect the microenvironmental hallmarks of aggressive patient tumours.

2016

AbstractTreatment of high-risk childhood neuroblastoma is a clinical challenge which has been hampered by a lack of reliable neuroblastoma mouse models for preclinical drug testing. We have previously established invasive and metastasising patient-derived orthotopic xenografts (PDXs) from high-risk neuroblastomas that retained the genotypes and phenotypes of patient tumours. Given the important role of the tumour microenvironment in tumour progression, metastasis, and treatment responses, here we analysed the tumour microenvironment of five neuroblastoma PDXs in detail. The PDXs resembled their parent tumours and retained important stromal hallmarks of aggressive lesions including rich bloo…

0301 basic medicinePathologymedicine.medical_specialtyCancer ResearchStromal cellGenotypeTumour stromaBiologyPolymorphism Single NucleotideMetastasisMetastasisPaediatric cancer03 medical and health sciencesMiceNeuroblastoma0302 clinical medicineNeuroblastomamedicineTumor MicroenvironmentAnimalsHumansPatient-derived xenograft (PDX)Tumor microenvironmentTumour microenvironmentNeovascularization Pathologicmedicine.diseaseXenograft Model Antitumor AssaysDisease Models Animal030104 developmental biologyLymphatic systemOncology030220 oncology & carcinogenesisCancer-Associated FibroblastsImmunohistochemistryBlood VesselsChildhood NeuroblastomaCancer letters
researchProduct

Lymphatic Endothelial Cells Control Initiation of Lymph Node Organogenesis

2017

Lymph nodes (LNs) are strategically situated throughout the body at junctures of the blood vascular and lymphatic systems to direct immune responses against antigens draining from peripheral tissues. The current paradigm describes LN development as a programmed process that is governed through the interaction between mesenchymal lymphoid tissue organizer (LTo) cells and hematopoietic lymphoid tissue inducer (LTi) cells. Using cell-type-specific ablation of key molecules involved in lymphoid organogenesis, we found that initiation of LN development is dependent on LTi-cell-mediated activation of lymphatic endothelial cells (LECs) and that engagement of mesenchymal stromal cells is a succeedi…

0301 basic medicinePathologymedicine.medical_specialtygovernment.form_of_governmentOrganogenesis[SDV]Life Sciences [q-bio]Immunology610 Medicine & healthMice TransgenicBiologyChoristoma10263 Institute of Experimental Immunology03 medical and health sciencesMiceImmune systemLymphotoxin beta ReceptormedicineLymph node stromal cellImmunology and AllergyAnimalsLymph nodeCells CulturedComputingMilieux_MISCELLANEOUS2403 ImmunologyReceptor Activator of Nuclear Factor-kappa BMesenchymal stem cellNF-kappa BEndothelial CellsCell DifferentiationMesenchymal Stem Cells2725 Infectious DiseasesEmbryo MammalianCell biologyMice Inbred C57BLHaematopoiesisLymphatic EndotheliumReceptors Lysosphingolipid030104 developmental biologyInfectious Diseasesmedicine.anatomical_structureLymphatic system2723 Immunology and Allergygovernment570 Life sciences; biology[SDV.IMM]Life Sciences [q-bio]/ImmunologyLymphLymph NodesSignal Transduction
researchProduct

Wharton’s Jelly Mesenchymal Stromal Cells from Human Umbilical Cord: a Close-up on Immunomodulatory Molecules Featured In Situ and In Vitro

2019

Therapeutic options for end-stage organ failure are often limited to whole organ transplantation. The tolerance or rejection of the transplanted organ is driven by both early non-specific innate and specific adaptive responses. The use of mesenchymal stromal cells (MSCs) is considered a promising tool in regenerative medicine. Human umbilical cord (HUC) is an easily available source of MSCs, without relevant ethical issues. Moreover, Wharton's jelly-derived MSCs (WJ-MSCs), showed consistent immunomodulatory features that may be useful to promote immune tolerance in the host after transplantation. Few data are available on the phenotype of WJ-MSCs in situ. We investigated the expression of i…

0301 basic medicineSettore BIO/17 - IstologiaB7 AntigensT cellIn Vitro TechniquesBiologyLymphocyte ActivationRegenerative medicineCell therapyUmbilical CordImmune toleranceImmunomodulation03 medical and health sciences0302 clinical medicineWharton's jellymedicineHumansWharton JellyCD276Cells CulturedCell ProliferationStem cellMesenchymal stem cellCell DifferentiationMesenchymal Stem CellsHuman umbilical cordCell biologyTransplantationTolerance induction030104 developmental biologymedicine.anatomical_structureB7-H3030220 oncology & carcinogenesisLymphocyte inhibitionRegenerative medicineCytokinesWharton’s jelly mesenchymal stromal cellsStem cell
researchProduct

Comparative study of the production of soluble factors in human placenta-derived mesenchymal stromal/stem cells grown in adherent conditions or as ag…

2019

Abstract Different approaches have been studied in both preclinical and clinical settings to develop cell-based therapies and/or engineered cell-based therapies to better integrate grafts with the host. In these techniques, much attention is addressed to the use of adult stem cells such as mesenchymal stem cells (MSCs), but identifying and obtaining sufficient numbers of therapeutic cells, and the right route of administration, is often a challenge. In this study, we tested the feasibility of encapsulating human amnion-derived MSCs (hAMSCs) in a semipermeable and biocompatible fiber as a new approach for regenerative medicine. Our data showed that hAMSCs aggregated in the device constitutes…

0301 basic medicineStromal cellAngiogenesisCell SurvivalPlacentaCellBiophysicsCell Culture TechniquesBiocompatible MaterialsBiologyParacrine effectsBiochemistryRegenerative medicineImmunomodulation03 medical and health sciences0302 clinical medicineImmune systemCell MovementPregnancymedicineCell AdhesionHuman Umbilical Vein Endothelial CellsHumansImmunologic FactorsAmnionMolecular BiologyCell AggregationSettore MED/04 - Patologia GeneraleCatheter-like devicePlacenta-derived stromal/stem cellsSettore BIO/16 - Anatomia UmanaMesenchymal stem cellMesenchymal Stem CellsCell BiologyCells Immobilized030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisRegenerative medicineCancer researchAngiogenesis Inducing AgentsFemaleAngiogenesisStem cellAdult stem cell
researchProduct

Chronic myelogenous leukaemia exosomes modulate bone marrow microenvironment through activation of epidermal growth factor receptor

2016

Abstract Chronic myelogenous leukaemia (CML) is a clonal myeloproliferative disorder. Recent evidence indicates that altered crosstalk between CML and mesenchymal stromal cells may affect leukaemia survival; moreover, vesicles released by both tumour and non‐tumour cells into the microenvironment provide a suitable niche for cancer cell growth and survival. We previously demonstrated that leukaemic and stromal cells establish an exosome‐mediated bidirectional crosstalk leading to the production of IL8 in stromal cells, thus sustaining the survival of CML cells. Human cell lines used are LAMA84 (CML cells), HS5 (stromal cells) and bone marrow primary stromal cells; gene expression and protei…

0301 basic medicineStromal cellchronic myeloid leukaemiaEGFRBone Marrow CellsexosomesBiologyInterleukin 8AmphiregulinBone Marrow Stromal Cell03 medical and health sciencesAmphiregulinSettore BIO/13 - Biologia Applicatahemic and lymphatic diseasesCell Line TumorLeukemia Myelogenous Chronic BCR-ABL PositivemedicineCell AdhesionHumansInterleukin 8Epidermal growth factor receptorRNA MessengerPhosphorylationRNA Small InterferingAnnexin A2SNAILMesenchymal stem cellInterleukin-8Cell BiologyOriginal ArticlesMicrovesiclesCell biologyErbB Receptors030104 developmental biologymedicine.anatomical_structureCellular MicroenvironmentMatrix Metalloproteinase 9Cancer cellChronic Myelogenous Leukemia Exosomes; Interleukin 8; Bone Marrow Stromal Cells; EGFRbiology.proteinMolecular MedicineOriginal ArticleBone marrowSnail Family Transcription FactorsChronic Myelogenous Leukemia ExosomeStromal Cellsepidermal growth factor receptor
researchProduct

Lymph node - an organ for T-cell activation and pathogen defense.

2016

The immune system is a multicentered organ that is characterized by intimate interactions between its cellular components to efficiently ward off invading pathogens. A key constituent of this organ system is the distinct migratory activity of its cellular elements. The lymph node represents a pivotal meeting point of immune cells where adaptive immunity is induced and regulated. Additionally, besides barrier tissues, the lymph node is a critical organ where invading pathogens need to be eliminated in order to prevent systemic distribution of virulent microbes. Here, we explain how the lymph node is structurally and functionally organized to fulfill these two critical functions - pathogen de…

0301 basic medicineT cellImmunologyAntigen presentationContext (language use)BiologyAdaptive ImmunityCD8-Positive T-LymphocytesLymphocyte Activation03 medical and health sciences0302 clinical medicineImmune systemCell MovementmedicineLymph node stromal cellImmunology and AllergyCytotoxic T cellAnimalsHumansLymph nodeAntigens ViralAntigen PresentationDendritic CellsAcquired immune system030104 developmental biologymedicine.anatomical_structureVirus DiseasesImmunologyHost-Pathogen InteractionsLymph Nodes030215 immunologyImmunological reviews
researchProduct